American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
American Journal of Medical Case Reports. 2015, 3(12), 399-402
DOI: 10.12691/ajmcr-3-12-4
Open AccessCase Report

Giant Prolactinoma: Case Report and Review of Literature

Khalid S.Aljabri1, , Samia A. Bokhari1 and Ahmad Akl1

1Department of Endocrinology, King Fahad Armed Forces Hospital, Jeddah, Kingdom of Saudi Arabia

Pub. Date: November 18, 2015

Cite this paper:
Khalid S.Aljabri, Samia A. Bokhari and Ahmad Akl. Giant Prolactinoma: Case Report and Review of Literature. American Journal of Medical Case Reports. 2015; 3(12):399-402. doi: 10.12691/ajmcr-3-12-4


Prolactin (PRL) secreting adenomas are the most common secreting pituitary tumors, accounting for approximately 45% of all pituitary tumours. Giant prolactinomas are a rare subset of macroadenomas, characterized by large size (more than 40 mm in diameter (an arbitrary size), high aggressiveness and massive extrasellar involvement. We describe an unusual giant prolactin producing macroadenoma of pituitary gland in female patients with type 2 diabetes mellitus and its response to cabergoline.

giant prolactinoma dopamine agonist

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


Figure of 2


[1]  Ciccarelli, A., Daly, A.F. & Beckers, A.The epidemiology of prolactinomas. Pituitary 2005, 8:3-6.
[2]  Shrivastava RK, Arginteanu MS, King WA & Post KD. Giant prolactinomas: clinical management and long-term follow up. Journal of Neurosurgery 2002, 97: 299-306.
[3]  Delgrange, E., Trouillas, J., Maiter, D. et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism 1997, 82: 2102-2107.
[4]  Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA & Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clinical Endocrinology 2003,58: 662-670.
[5]  Shimon, I., Benbassat, C. & Hadani, M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. European Journal of Endocrinology 2007, 156: 225-231.
[6]  Davis JR, Sheppard MC, Health DA: Giant invasive prolactinoma: a case report and review of nine further cases. Q J Med 1990, 74:227-238.
[7]  Ciric I, Mikhael M, Stafford T, Lawson L, Garces R: Transsphenoidal microsurgery of pituitary macroadenoma with long-term follow up results. J Neurosurg 1983, 59:395-401.
[8]  Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003, 6: 19-27.
[9]  Yu, C., Wu, Z. & Gong, J. Combined treatment of invasive giant prolactinomas. Pituitary 2005, 8: 61-65.
[10]  Mindermann T & Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clinical Endocrinology 1994, 41: 359-364.
[11]  Etienne Delgrange, Gerald Raverot1, Marie Bex, Pia Burman,Be´ne´ dicte Decoudier, France Devuyst, Ulla Feldt-Rasmussen,Marianne Andersen, Dominique Maiter. Giant prolactinomas in women. European Journal of Endocrinology 2014, 170: 31-38.
[12]  Lundberg PO, Osterman PO &Wide L. Serum prolactin in patients with hypothalamus and pituitary disorders. Journal of Neurosurgery 1981, 55: 194-199.
[13]  Cho EH, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ, Kim MS:Efficacy and safety of cabergoline as first line treatmentfor invasive giant prolactinoma. J Korean Med Sci 2009, 24:874-878.
[14]  St-Jean, E., Blain, F. & Comtois, R. (1996) High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clinical Endocrinology 1996, 44:305-309.
[15]  Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Review 2006, 27: 485-534.
[16]  Oruckaptan HH, Senmevsim O, Ozcan OE & Ozgen T. Pituitary adenomas: results of 684 surgically treated patients and review of literature. Surgical Neurology 2000, 53: 211-219.
[17]  Melmed, S., Casanueva, F.F., Hoffman, A.R. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2001, 96: 273-288.
[18]  Dash, S., Annamalai, A.K., Simpson, H.L. et al. Acute shrinkage of a giant prolactinoma, masquerading as an erosive skull base tumour, with cabergoline. QJM 2013, 106: 85.
[19]  Acharya SV, Gopal RA, Menon PS, Bandgar TR, Shah NS: Giant prolactinoma and effectiveness of medical management. Endocrinol Pract 2010, 16:42-46.
[20]  Saeki N, Nakamura M, Sunami K & Yamaura A. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocrine Journal1998, 45: 529-537.
[21]  Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR &MacFarlane IA. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clinical Endocrinology 2002, 52: 43-49.
[22]  Odin P, Oehlwein C, Storch A, Polzer U, Werner G, Renner R,Shing M, Ludolph A & Schuler P. Efficacy and safety of high-dose cabergoline in Parkinson’s disease. Acta Neurologica Scandinavica 2006, 113: 18-24.
[23]  Pinero A, Marcos-Alberca P & Fortes J. Cabergoline-related severe restrictive mitral regurgitation. New England Journal of Medicine 1997, 337: 581-588.